Dror Ortho-Design's Losses Narrow, Cash Dwindles Amid R&D Cuts

TL;DR

**DROR is burning cash faster than it can raise it, making it a speculative bet on future product commercialization that looks increasingly unlikely.**

AI Summary

Dror Ortho-Design, Inc. (DROR) reported a net loss of $759,338 for the three months ended June 30, 2025, a significant improvement from the $1,506,790 net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $1,335,461, down from $2,815,253 in the prior year. The company has not yet generated any revenues and continues to operate at a loss, with an accumulated deficit reaching $20,842,117 as of June 30, 2025. Cash significantly decreased from $549,444 at December 31, 2024, to $64,481 at June 30, 2025. Total current liabilities surged to $1,639,241 from $906,738, primarily due to new notes payable of $300,513 and a derivative liability of $212,179. Research and development expenses decreased by 26% to $563,672 for the six months ended June 30, 2025, compared to $762,873 in the prior year, while share-based compensation plummeted from $1,311,625 to $39,170 over the same period. The company raised $500,000 from loans in the first half of 2025 to support its operations.

Why It Matters

Dror Ortho-Design's continued lack of revenue and substantial accumulated deficit of $20,842,117 as of June 30, 2025, signals high risk for investors, indicating a heavy reliance on external financing. The sharp decline in cash to $64,481 and the significant increase in current liabilities to $1,639,241 highlight severe liquidity challenges, potentially impacting the company's ability to fund ongoing research and development of its orthodontic alignment platform. For employees, this financial instability could mean job insecurity or delayed compensation. In a competitive medical device market, DROR's inability to reach the sales stage puts it at a significant disadvantage against established players, making its long-term viability questionable without substantial new capital infusions.

Risk Assessment

Risk Level: high — The company has an accumulated deficit of $20,842,117 as of June 30, 2025, and has not yet generated any revenues, indicating severe financial distress. Cash reserves plummeted from $549,444 at December 31, 2024, to $64,481 at June 30, 2025, while total current liabilities increased by 80% to $1,639,241, demonstrating significant liquidity risk and a going concern issue.

Analyst Insight

Investors should avoid DROR given its severe liquidity issues, lack of revenue, and substantial accumulated deficit. The company's reliance on external financing and the significant increase in liabilities suggest a high probability of further dilution or bankruptcy, making it an unsuitable investment.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$ 132,616

total Debt

$ 1,796,901

net Income

$ -1,335,461

eps

$ -0.00

gross Margin

N/A

cash Position

$ 64,481

revenue Growth

N/A

Key Numbers

• $20.8M — Accumulated Deficit (Increased from $19.5M at Dec 31, 2024, highlighting ongoing losses.)
• $64,481 — Cash (Decreased by 88% from $549,444 at Dec 31, 2024, indicating severe liquidity issues.)
• $1.6M — Total Current Liabilities (Increased by 80% from $906,738 at Dec 31, 2024, primarily due to new debt.)
• $1.3M — Net Loss (Six Months) (Improved from $2.8M in prior year, but still substantial.)
• $500,000 — Proceeds from Loans (Raised in H1 2025, critical for continued operations but insufficient to cover liabilities.)
• 956,997,116 — Common Shares Outstanding (Consistent since Dec 31, 2024, but significantly higher than 495,454,546 in H1 2024 due to reverse recapitalization.)
• $563,672 — R&D Expenses (Six Months) (Decreased by 26% from $762,873 in prior year, potentially impacting product development.)
• $39,170 — Share-based Compensation (Six Months) (Plummeted from $1,311,625 in prior year, reducing non-cash expenses.)

Key Players & Entities

• Dror Ortho-Design, Inc. (company) — registrant
• Private Dror (company) — accounting acquirer in reverse recapitalization
• SEC (regulator) — filing oversight
• $20,842,117 (dollar_amount) — accumulated deficit as of June 30, 2025
• $64,481 (dollar_amount) — cash balance as of June 30, 2025
• $549,444 (dollar_amount) — cash balance as of December 31, 2024
• $1,639,241 (dollar_amount) — total current liabilities as of June 30, 2025
• $906,738 (dollar_amount) — total current liabilities as of December 31, 2024
• $500,000 (dollar_amount) — proceeds from loans in the first half of 2025
• OTC Pink Market (market) — where DROR stock is quoted

FAQ

Risk Factors

• Severe Liquidity Constraints [high — financial]: Cash decreased by 88% from $549,444 to $64,481 in six months, while total current liabilities increased by 80% to $1,639,241. This significant deterioration in liquidity, driven by new notes payable of $300,513 and a derivative liability of $212,179, poses a substantial risk to the company's ability to meet its short-term obligations.
• Growing Accumulated Deficit [high — financial]: The accumulated deficit has reached $20.8 million as of June 30, 2025, an increase from $19.5 million at the end of 2024. This ongoing trend of losses, despite a reduction in net loss for the six-month period, indicates a persistent inability to generate profits and raises concerns about long-term financial viability.
• Dependence on External Financing [medium — operational]: The company raised $500,000 from loans in the first half of 2025 to support operations. This reliance on debt financing, coupled with the current liquidity crunch, suggests a precarious operational funding situation and potential challenges in securing future capital.
• Reduced R&D Spending [medium — operational]: Research and development expenses decreased by 26% to $563,672 for the six months ended June 30, 2025, compared to $762,873 in the prior year. While this may be a cost-saving measure, a significant reduction in R&D could hinder future product development and innovation, impacting long-term competitiveness.
• Derivative Liability Impact [medium — financial]: The company recognized a new derivative liability of $212,179 as of June 30, 2025, contributing to the surge in current liabilities. Fluctuations in the fair value of derivatives can introduce volatility into financial results and increase financial risk.

Industry Context

The orthopedic design and medical device industry is highly competitive and capital-intensive, requiring significant investment in research and development. Companies in this sector face stringent regulatory hurdles and must continuously innovate to gain market share. Dror Ortho-Design appears to be in an early-stage development phase, as evidenced by its lack of revenue and substantial operating losses.

Regulatory Implications

As a medical device company, Dror Ortho-Design is subject to rigorous regulatory oversight from bodies like the FDA. Compliance with manufacturing standards, clinical trial requirements, and post-market surveillance is critical. Any delays or failures in obtaining regulatory approvals can significantly impact product launch timelines and market access.

What Investors Should Do

1. Monitor cash burn rate and future financing activities.
2. Evaluate the sustainability of reduced operating expenses.
3. Scrutinize the nature and impact of new liabilities.
4. Assess the impact of the increased share count.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reported a net loss of $759,338 for the quarter and $1,335,461 for the six months, with cash falling to $64,481 and current liabilities rising to $1,639,241.
• 2025-01-01: Beginning of First Half 2025 — Company raised $500,000 from loans to support operations, indicating a need for external funding.
• 2024-12-31: End of Fiscal Year 2024 — Reported cash of $549,444 and accumulated deficit of $19.5 million.
• 2024-06-30: End of Second Quarter 2024 — Reported a net loss of $1,506,790 for the quarter and $2,815,253 for the six months, with significantly higher share-based compensation expenses.

Glossary

Accumulated deficit

The total net losses of a company since its inception, minus any net profits. It represents a negative balance in retained earnings. (Indicates the company has consistently operated at a loss, reaching $20.8 million, highlighting ongoing financial challenges.)

Derivative liability

An obligation arising from a financial derivative contract whose value is derived from an underlying asset, index, or rate. It represents a potential future payment or obligation. (A new derivative liability of $212,179 was recognized, contributing to the increase in current liabilities and adding financial complexity.)

Share-based compensation

Compensation provided to employees in the form of stock options, restricted stock, or other equity awards, rather than cash. (A significant decrease from $1,311,625 to $39,170 in six months reduced non-cash expenses, but the prior period's high value may reflect past equity grants.)

Weighted-average common shares outstanding

The average number of a company's common shares outstanding over a specific period, used for calculating earnings per share. (The number of shares outstanding more than doubled from 495,454,546 to 956,997,116, indicating a significant event like a reverse stock split or recapitalization, which impacts per-share metrics.)

Registration Rights Agreement liability

A liability associated with an agreement that grants holders of certain securities the right to have their shares registered with the SEC, allowing them to be sold publicly. (A $520,000 liability related to this agreement is present on both the June 30, 2025, and December 31, 2024, balance sheets, suggesting a contingent obligation or deferred cost.)

Year-Over-Year Comparison

Compared to the six months ended June 30, 2024, Dror Ortho-Design has significantly reduced its net loss from $2.8 million to $1.3 million. However, this improvement comes with a severe deterioration in liquidity, as cash has plummeted by 88% to $64,481, while current liabilities have surged by 80% to $1.6 million. Operating expenses have also seen a notable reduction, primarily driven by a drastic decrease in share-based compensation from $1.3 million to $39,170, and a 26% cut in R&D expenses. The company has also seen a substantial increase in its outstanding shares due to a reverse recapitalization.

Key Financial Figures

• $0.0001 — he registrant's common stock, par value $0.0001 per share, as of August 14, 2025 was 95

Filing Documents

• ea0252818-10q_dror.htm (10-Q) — 456KB
• ea025281801ex31-1_dror.htm (EX-31.1) — 10KB
• ea025281801ex31-2_dror.htm (EX-31.2) — 10KB
• ea025281801ex32-1_dror.htm (EX-32.1) — 4KB
• ea025281801ex32-2_dror.htm (EX-32.2) — 4KB
• 0001213900-25-076768.txt ( ) — 3057KB
• dror-20250630.xsd (EX-101.SCH) — 25KB
• dror-20250630_cal.xml (EX-101.CAL) — 20KB
• dror-20250630_def.xml (EX-101.DEF) — 143KB
• dror-20250630_lab.xml (EX-101.LAB) — 246KB
• dror-20250630_pre.xml (EX-101.PRE) — 150KB
• ea0252818-10q_dror_htm.xml (XML) — 239KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 1 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 24 Item 4.

Controls and Procedures

Controls and Procedures 24

OTHER INFORMATION

PART II. OTHER INFORMATION 25 Item 1.

Legal Proceedings

Legal Proceedings 25 Item 1A.

Risk Factors

Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26 Item 3. Defaults Upon Senior Securities 26 Item 4. Mine Safety Disclosures 26 Item 5. Other Information 26 Item 6. Exhibits 27

Signatures

Signatures 28 i DROR ORTHO-DESIGN, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars)

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements June 30, 2025 December 31, 2024 Unaudited Audited Assets Current Assets: Cash $ 64,481 $ 549,444 Receivables and prepaid expenses 46,443 89,139 Total Current Assets 110,924 638,583 Non-current Assets: Property and equipment at cost, net of accumulated depreciation 21,692 24,142 Total Assets 132,616 662,725 Liabilities And Stockholders' DEFICIT Current Liabilities: Accounts payable $ 405,859 $ 215,359 Accrued expenses and other payables 200,690 171,379 Notes payable 300,513 - Derivative liability 212,179 - Registration Rights Agreement liability 520,000 520,000 Total Current Liabilities 1,639,241 906,738 Non-current Liabilities: Accrued severance 157,660 123,981 Total Liabilities 1,796,901 1,030,719 Commitments and Contingencies (Note 6) Stockholders' Deficit Preferred A Stock, $ 0.0001 par value, 12,500,000 shares authorized; 5,847,937 shares outstanding at June 30, 2025 and December 31, 2024, respectively 585 585 Common stock, $ 0.0001 par value; 3,254,475,740 shares authorized; 956,997,116 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 95,699 95,699 Additional paid-in capital 19,081,548 19,042,378 Accumulated deficit ( 20,842,117 ) ( 19,506,656 ) Total Stockholders' Deficit ( 1,664,285 ) ( 367,994 ) Total Liabilities and Stockholders' Deficit $ 132,616 $ 662,725 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 DROR ORTHO-DESIGN, INC. CONDENSED STATEMENTS OF OPERATIONS (U.S. dollars, except share and per share amounts) Three Months Ended Six Months Ended June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Unaudited Unaudited Operating Expenses Research and development $ 324,068 $ 389,216 $ 563,672 $ 762,873 General and administrative expenses 391,494 333,274 705,123 718,838 Share

View Full Filing

View this 10-Q filing on SEC EDGAR